載入...
Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus
OBJECTIVES: Belimumab, an anti-B lymphocyte stimulator (BLyS) human monoclonal antibody, was approved in the United States, Canada and European Union for the treatment of the patients with systemic lupus erythematosus (SLE). However, belimumab had not been evaluated in Japanese patients. The objecti...
Na minha lista:
| 發表在: | J Drug Assess |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Maney Publishing
2013
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4937663/ https://ncbi.nlm.nih.gov/pubmed/27536436 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/21556660.2013.792823 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|